Pascal M.
- Country
- France
- Department
- pneumology
Research Overview
- Comparison of Initial Dual Oral Therapy with Riociguat and Macitentan Versus Standard Monotherapy in Inoperable Chronic Thromboembolic Pulmonary Hypertension
- Evaluation of Sotatercept Plus Background Therapy Versus Placebo in Intermediate- and High-risk Pulmonary Arterial Hypertension: A Phase 3 Randomized Study
- Comparison of Initial Dual Oral Therapy with Tadalafil and Ambrisentan Versus Tadalafil Monotherapy in Pulmonary Arterial Hypertension with Cardiovascular Comorbidities
Data & Insights
Has run more than one trial at 24 of 83 partner sites.
Specializations
Pulmonary Hypertension Research
This investigator specializes in various forms of pulmonary hypertension, with particular emphasis on therapeutic interventions for different PH manifestations.
- Pulmonary Arterial Hypertension (PAH)
- COPD-associated Pulmonary Hypertension
- Chronic Thromboembolic Pulmonary Hypertension
The research focus includes innovative treatment approaches for newly diagnosed and treatment-naïve patients.
Novel Therapeutics
The investigator explores advanced therapeutic options in pulmonary vascular medicine, particularly focusing on emerging treatments.
- Sotatercept Development
- Dual Oral Treatment Strategies
- Long-term Treatment Outcomes
Special attention is given to evaluating treatment efficacy in high-risk patient populations.
Clinical Management
Research activities concentrate on therapeutic management strategies for complex pulmonary conditions.
- Risk Assessment Approaches
- Treatment Response Evaluation
- Inoperable CTEPH Management
The focus extends to developing comprehensive treatment protocols for various patient subgroups.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.